Status:
NOT_YET_RECRUITING
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions:
Chronic Myelogenous Leukemia
CML Chronic Phase
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. Flumatinib is the first ap...
Eligibility Criteria
Inclusion
- Signed informed consent form.
- Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
- CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.
- Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.
- ECOG performance status of 0-1 and no worsening within 2 weeks before the first dose.
- Life expectancy ≥ 12 weeks.
- Men or women should be using adequate contraceptive measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study.
- Females must have evidence of non-childbearing potential.
Exclusion
- CML-CP patients who have acquired CCyR and have not lost it.
- Patients with CML-CP who have progressed to AP or blast phase(BP.)
- Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood.
- Patients with CML-AP who have progressed to BP.
- Previous treatment with a BCR-ABL1 TKI allosteric inhibitor .
- Impaired cardiac function including any one of the following:
- Resting corrected QT interval (QTc) \> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
- Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,
- Left ventricular ejection fraction (LVEF) ≤ 50%.
- Myocardial infarction occurred within 6 months of the first scheduled dose of study drug.;
- Congestive heart failure occurred within 6 months of the first scheduled dose of study drug.;
- Uncontrollable angina.
- History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
- Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes).
- Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.
- Severe infection within 4 weeks prior to the first scheduled dose of study drug
- Inadequate other organ function.
- History of other malignancies.
- History of hypersensitivity to any active or inactive ingredient of HS-10382 and flumatinib.
- History of neuropathy or mental disorders, including epilepsy and dementia.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Key Trial Info
Start Date :
July 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 8 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06530810
Start Date
July 31 2024
End Date
May 8 2028
Last Update
July 31 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.